Company intelligence / Profile preview
Herophilus
- Ownership
- Private
- Development stage
- Preclinical
Overview
Herophilus leverages human brain organoids, scaled biology automation, and machine learning to systematically discover novel drugs targeting complex brain diseases. The company has pioneered multi-modal phenotypic screening in vitro to identify new therapeutic targets for disorders like Rett syndrome, Alzheimer’s disease, and schizophrenia. As of late 2023/early 2024 their programs are primarily in preclinical or early validation phases; no published clinical results yet.[1][2][3]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesPotentially others via phenotypic screening and organoid models (not explicitly listed)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Herophilus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Herophilus.